抗真菌新药泊沙康唑的药动学特征及治疗药物监测研究进展

马骁,赵莉,王晓星,杜雯雯,刘晓

中国药学杂志 ›› 2016, Vol. 51 ›› Issue (6) : 433-436.

PDF(584 KB)
中国药学杂志
PDF(584 KB)
中国药学杂志 ›› 2016, Vol. 51 ›› Issue (6) : 433-436. DOI: 10.11669/cpj.2016.06.002
综 述

抗真菌新药泊沙康唑的药动学特征及治疗药物监测研究进展

  • 马骁a,赵莉b,王晓星b,杜雯雯b,刘晓b*
作者信息 +

Advances in Research on Pharmacokinetic Characteristics and Therapeutic Drug Monitoring for the Antifungal Extended-Spectrum Posaconazole

  • MA Xiaoa,ZHAO Lib,WANG Xiao-xingb,DU Wen-wenb,LIU Xiaob*
Author information +
文章历史 +

摘要

由于药动学特征的差异以及药物相互作用影响,三唑类广谱抗真菌药泊沙康唑的体内血药浓度波动明显。笔者以近年来的文献研究为基础,对泊沙康唑的药理作用、药动学特点、药物相互作用和剂型差异等方面进行归纳,对治疗药物监测(TDM)的发展情况进行分析,进而尝试为泊沙康唑的个体化合理用药提供帮助。

Abstract

The wide fluctuation on blood concentration of triazole antifungal extended-spectrum drug posaconazole was exposed due to the pharmacokinetic differences and drug interaction. Based on the literatures in recent years, the pharmacological mechanism, pharmacokinetic characteristics,drug interactions and drug dosage forms were reviewed and introduced, prospects for the therapeutic drug monitoring were analyzed. And then try to provide a reference for the personalized medicine of posaconazole.

关键词

泊沙康唑 / 治疗药物监测 / 真菌感染

Key words

posaconazole / therapeutic drug monitoring / fungal infection

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
马骁,赵莉,王晓星,杜雯雯,刘晓. 抗真菌新药泊沙康唑的药动学特征及治疗药物监测研究进展[J]. 中国药学杂志, 2016, 51(6): 433-436 https://doi.org/10.11669/cpj.2016.06.002
MA Xiao,ZHAO Li,WANG Xiao-xing,DU Wen-wen,LIU Xiao. Advances in Research on Pharmacokinetic Characteristics and Therapeutic Drug Monitoring for the Antifungal Extended-Spectrum Posaconazole[J]. Chinese Pharmaceutical Journal, 2016, 51(6): 433-436 https://doi.org/10.11669/cpj.2016.06.002
中图分类号： R969.1   

参考文献

[1] WANG X J,WAN Z,LI R Y,et al. Antifungal susceptibility testing of clinical isolates of fluconazole-resistant Candida spp. and itraconazoleresistant Aspergillus funmigates to posaconazole[J]. Chin J Mycol(中国真菌学杂志),2014,9(2):75-78.
[2] ZHENG J M,ZHANG Y X. Posaconazole,a new antifungal drug[J]. World Clin Drugs(世界临床药物),2007,28(9):546-549.
[3] BAXTER C G,MARSHALL A,ROBERTS M,et al. Peripheral neuropathy in patients on long-term triazole antifungal therapy[J]. J Antimicrob Chemother,2011,66(9):2136-2139.
[4] KRISHNA G,MOTON A,MA L,et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers[J]. Antimicrob Agents Chemother,2009,53(3):958-966.
[5] VAN BURIK J A,HARE R S,SOLOMON H F,et al. Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases [J]. Clin Infect Dis,2006,42(7):61-65.
[6] FDA. Highlights of prescribing information[EB/OL]. 2010,09:1-23 [2014-09-23]. http://www. accessdata. fda. gov/drugsatfda_docs/label/2010/02 2003s008,022027s001lbl. pdf
[7] Martindale-The Complete Drug Reference [M]. 36th ed. UK: The Pharmaceutical Press,2009:544-545.
[8] SABATELLI F,PATEL R,MANN P A,et al. In vitro activities of posaconazole,fluconazole,itraconazole,voriconazole,and amphotericin B against a large collection of clinically important molds and yeasts [J]. Antimicrob Agents Chemother,2006,50(6):2009-2015.
[9] WALSH T J,RAAD I,PATTERSON T F,et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial[J]. Clin Infect Dis,2007,44(1):2-12.
[10] RESTREPO A,TOBN A,CLARK B,et al. Salvage treatment of histoplasmosis with posaconazole[J]. J Infect,2007,54(4):319-327.
[11] WARRILOW A G,MELO N,MARTEL C M,et al. Expression,purification,and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B[J]. Antimicrob Agents Chemother,2010,54(10):4225-4234.
[12] NAGAPPAN V,DERESINSKI S. Reviews of anti-infective agents: Posaconazole: A broad-spectrum triazole antifungal agent[J]. Clin Infect Dis,2007,45(12):1610-1617.
[13] ULLMANN A J,CORNELY O A,BURCHARDT A,et al. Pharmacokinetics,safety,and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection[J]. Antimicrob Agents Chemother,2006,50(2):658-666.
[14] EZZEF F,WEXLER D,COURTNEY R,et al.Oral bioavailability of posaconazole in fasted healthy subjects: Comparison between three regimens and basis for clinical dosage recommendations[J]. Clin Pharmacokinet,2005,44(2):211-220.
[15] CONTE J E J R,GOLDEN J A,KRISHNA G,et al. Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects[J]. Antimicrob Agents Chemother,2009,53(2):703-707.
[16] KRIETER P,FLANNERY B,MUSICK T,et al. Disposition of posaconazole following single-dose oral administration in healthy subjects[J]. Antimicrob Agents Chemother,2004,48(9):3543-3551.
[17] WANG C J,XIE D D. Posaconazole,antifungal agent[J]. World Clin Drugs(世界临床药物),2007,28(8):509.
[18] COURTNEY R,PAI S,LAUGHLIN M,et al. Pharmacokinetics,safety and tolerability of oral posaconazole administered in single and multiple doses in healthy adults[J]. Antimicrob Agents Chemother,2003,47(9):2788-2795.
[19] WEXLER D,COURTNEY R,RICHARDS W,et al. Effect of posaconazole on cytochrome P450 enzymes: A randomized,open-label,two-way crossover study[J]. Eur J Pharm Sci,2004,21(5):645-653.
[20] LI Y,THEURETZBACHER U,CLANCY C J,et al. Pharmacokinetic/pharmacodynamic profile of posaconazole[J]. Clin Pharmacokinet,2010,49(6):379-396.
[21] FDA. Highlights of prescribing information[EB/OL]. 2014,03:1-38 [2014-09-23]. http://www. accessdata. fda. gov/drugsatfda_docs/label/2014/205596s000lbl. pdf
[22] COURTNEY R,SANSONE A,SMITH W,et al. Posaconazole pharmacokinetics,safety,and tolerability in subjects with varying degrees of chronic renal disease[J]. J Clin Pharmacol,2005,45(2):185-192.
[23] LUKE D R,TOMASZEWSKI K,DAMLE B,et al. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD) [J]. J Pharm Sci,2010,99(8):3291-3301.
[24] SANSONE-PARSONS A,KRISHNA G,SIMON J,et al. Effects of age,gender,and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers[J]. Antimicrob Agents Chemother,2007,51(2):495-502.
[25] GUBBINS P O,KRISHNA G,SANSONE-PARSONS A,et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients[J]. Antimicrob Agents Chemother,2006,50(6):1993-1999.
[26] KONTOYIANNIS D P,LEWIS R E. How I treat mucormycosis [J]. Blood,2011,118(5):1216-1224.
[27] JAIN R,POTTINGER P. The effect of gastric acid on the absorption of posaconazole[J]. Clin Infect Dis,2008,46(10):1627.
[28] LEKAKIS L J,LAWSON A,PRANTE J,et al. Fatal rhizopus pneumonia in allogeneic stem cell transplant patients despite posaconazole prophylaxis:Two cases and review of the literature[J]. Biol Blood Marrow Transplant,2009,15(8):991-995.
[29] ANDES D,PASCUAL A,MARCHETTI O. Antifungal therapeutic drug monitoring:Established and emerging indications[J]. Antimicrob Agents Chemother,2009,53(1):24-34.
[30] EIDEN C,MENIANE J C,PEYRIRE H,et al. Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: Influence of food intake[J]. Eur J Clin Microbiol Infect Dis,2012,31(2):161-167.
[31] JANG S H,COLANGELO P M,GOBBURU J V. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections:Evaluating the need to adjust doses based on drug concentrations in plasma[J]. Clin Pharmacol Ther,2010,88(1):115-119.
[32] SMITH J,ANDES D. Therapeutic drug monitoring of antifungals:Pharmacokinetics and pharmacodynamic considerations[J]. Ther Drug Monit,2008,30(2):167-172.
[33] ALMYROUDIS N G,SUTTON D A,FOTHERGILL A W,et al. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents[J]. Antimicrob Agents Chemother,2007,51(7):2587-2590.
[34] CAMPOLI P,AL ABDALLAH Q,ROBITAILLE R,et al. Concentration of antifungal agents within host cell membranes: A new paradigm governing the efficacy of prophylaxis[J]. Antimicrob Agents Chemother,2011,55(12):5732-5739.
[35] MOU L P,YAO Y U. Interpretation of clinical guide to histoplasmosis revised edition 2007 by Infectious Diseases Society of America[J]. World Notes on Antibiotics,2008,29(3):125-139.
[36] KRISHNA G,MOTON A,MA L,et al. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: A phase I,randomized,open-label,crossover study in healthy volunteers[J]. Clin Ther,2009,31(2):286-298.
[37] JAIN S,KAPOOR G. Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine[J]. Pediatr Blood Cancer,2010,54(5):783.
PDF(584 KB)

132

Accesses

0

Citation

Detail
段落导航
相关文章

/

〈 〉